DDInter675 DDInter1676
Esmolol, commonly marketed under the trade name Brevibloc, is a cardioselective beta-1 receptor blocker. It has a rapid onset but short duration of action without causing significant intrinsic sympathomimetic or membrane stabilizing activities at recommended therapeutic doses. It works by blocking beta-adrenergic receptors in the heart, which leads to decreased force and rate of heart contractions. Esmolol prevents the action of two naturally occurring substances: epinephrine and norepinephrine. The FDA withdrew its approval for the use of all parenteral dosage form drug products containing esmolol hydrochloride that supply 250 milligrams/milliliter of concentrated esmolol per 10-milliliter ampule. Other esmolol formulations are still available for use.
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Esmolol {u} (Compound) resembles {v} (Compound) Metipranolol
Esmolol {u} (Compound) resembles {v} (Compound) Acebutolol
Esmolol {u} (Compound) treats {v} (Disease) hypertension
Esmolol {u} (Compound) binds {v} (Gene) ADRB1
Esmolol {u} (Compound) upregulates {v} (Gene) CAB39
Esmolol {u} (Compound) downregulates {v} (Gene) JMJD6
Esmolol {u} (Compound) causes {v} (Side Effect) Hyperhidrosis
Esmolol (Compound) resembles Metipranolol (Compound)
Esmolol (Compound) resembles Acebutolol (Compound)
Esmolol (Compound) treats hypertension (Disease)
Esmolol (Compound) binds ADRB1 (Gene)
Esmolol (Compound) upregulates CAB39 (Gene)
Esmolol (Compound) downregulates JMJD6 (Gene)
Esmolol (Compound) causes Hyperhidrosis (Side Effect)